DK3485883T3 - Metoder til behandling af øjensygdomme forbundet med betændelse og vaskulær spredning - Google Patents
Metoder til behandling af øjensygdomme forbundet med betændelse og vaskulær spredning Download PDFInfo
- Publication number
- DK3485883T3 DK3485883T3 DK18207689.3T DK18207689T DK3485883T3 DK 3485883 T3 DK3485883 T3 DK 3485883T3 DK 18207689 T DK18207689 T DK 18207689T DK 3485883 T3 DK3485883 T3 DK 3485883T3
- Authority
- DK
- Denmark
- Prior art keywords
- inflammation
- treatment
- methods
- diseases related
- eye diseases
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4192—1,2,3-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4425—Pyridinium derivatives, e.g. pralidoxime, pyridostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/04—Amoebicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010905197A AU2010905197A0 (en) | 2010-11-24 | Methods of treating eye diseases associated with inflammation and vascular proliferation | |
| EP11843788.8A EP2642989B1 (en) | 2010-11-24 | 2011-11-10 | Methods of treating eye diseases associated with inflammation and vascular proliferation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3485883T3 true DK3485883T3 (da) | 2020-10-12 |
Family
ID=46145280
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11843788.8T DK2642989T3 (da) | 2010-11-24 | 2011-11-10 | Frengangsmåder til behandling af øjensygdomme associeret med inflammation og vaskulær proliferation |
| DK18207689.3T DK3485883T3 (da) | 2010-11-24 | 2011-11-10 | Metoder til behandling af øjensygdomme forbundet med betændelse og vaskulær spredning |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK11843788.8T DK2642989T3 (da) | 2010-11-24 | 2011-11-10 | Frengangsmåder til behandling af øjensygdomme associeret med inflammation og vaskulær proliferation |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US9839640B2 (da) |
| EP (2) | EP2642989B1 (da) |
| JP (1) | JP5942131B2 (da) |
| KR (1) | KR101899613B1 (da) |
| CN (1) | CN103228275B (da) |
| AU (1) | AU2011334592C1 (da) |
| CA (1) | CA2815390C (da) |
| DK (2) | DK2642989T3 (da) |
| ES (2) | ES2829620T3 (da) |
| HR (1) | HRP20190561T1 (da) |
| HU (1) | HUE042676T2 (da) |
| MX (1) | MX352517B (da) |
| NZ (1) | NZ609144A (da) |
| PL (1) | PL2642989T3 (da) |
| PT (1) | PT2642989T (da) |
| RS (1) | RS58603B1 (da) |
| SG (1) | SG189326A1 (da) |
| SI (1) | SI2642989T1 (da) |
| TR (1) | TR201904760T4 (da) |
| WO (1) | WO2012068612A1 (da) |
| ZA (1) | ZA201302638B (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2642989T (pt) | 2010-11-24 | 2019-04-23 | Occurx Pty Ltd | Métodos de tratamento de doenças oculares associadas a inflamação e proliferação vascular |
| JP7185631B2 (ja) | 2017-02-03 | 2022-12-07 | サータ セラピューティクス プロプライエタリー リミテッド | 抗線維化化合物 |
| CN110357789B (zh) * | 2018-04-11 | 2022-09-30 | 华东理工大学 | 作为dhodh抑制剂的n-取代丙烯酰胺衍生物及其制备和用途 |
| WO2021247900A1 (en) * | 2020-06-05 | 2021-12-09 | Occurx Pty. Ltd. | Compounds and methods for the treatment of eye disorders |
| WO2022197681A1 (en) * | 2021-03-17 | 2022-09-22 | Occurx Pty Ltd | Compounds for the treatment of disorders and salts and polymorphs thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09176003A (ja) | 1995-12-28 | 1997-07-08 | Tsumura & Co | 角膜治療剤 |
| WO1997029744A1 (fr) | 1996-02-15 | 1997-08-21 | Kissei Pharmaceutical Co., Ltd. | Inhibiteur de la neoformation de vaisseaux sanguins |
| JPH09278653A (ja) | 1996-04-05 | 1997-10-28 | Santen Pharmaceut Co Ltd | 網膜疾患治療剤 |
| JPH10259129A (ja) * | 1997-01-16 | 1998-09-29 | Kissei Pharmaceut Co Ltd | 血管新生阻害剤 |
| IL131216A (en) | 1997-02-14 | 2003-10-31 | Kissei Pharmaceutical | Drugs inhibiting progress of pterygium and postoperative recurrence of the same |
| JPH10330254A (ja) * | 1997-04-01 | 1998-12-15 | Kissei Pharmaceut Co Ltd | 翼状片の進行および術後の再発抑制剤 |
| US20070254055A1 (en) | 2003-11-21 | 2007-11-01 | Trustees Of Tufts College | Therapeutic Avenanthramide Compounds |
| WO2006073126A1 (ja) | 2005-01-06 | 2006-07-13 | Kissei Pharmaceutical Co., Ltd. | 慢性移植片対宿主症におけるドライアイの予防および治療剤 |
| EP2035369B1 (en) | 2006-07-05 | 2014-06-25 | Fibrotech Therapeutics PTY LTD | Therapeutic compounds |
| WO2008131481A1 (en) * | 2007-04-26 | 2008-11-06 | Fibrotech Therapeutics Pty Ltd | Treatment of mesangioproliferative diseases |
| KR20100047860A (ko) | 2007-07-06 | 2010-05-10 | 누온 테라피우틱스, 아이엔씨. | 신경병증 통증의 치료 |
| AU2008341010B2 (en) * | 2007-12-21 | 2013-04-18 | Certa Therapeutics Pty. Ltd. | Halogenated analogues of anti-fibrotic agents |
| US20100158905A1 (en) | 2008-12-19 | 2010-06-24 | Nuon Therapeutics, Inc. | Combination therapy of arthritis with tranilast |
| WO2010144959A1 (en) | 2009-06-18 | 2010-12-23 | Fibrotech Therapeutics Pty Ltd | Analogues of anti-fibrotic agents |
| IN2012DN03312A (da) | 2009-10-22 | 2015-10-23 | Fibrotech Therapeutics Pty Ltd | |
| PT2642989T (pt) | 2010-11-24 | 2019-04-23 | Occurx Pty Ltd | Métodos de tratamento de doenças oculares associadas a inflamação e proliferação vascular |
-
2011
- 2011-11-10 PT PT11843788T patent/PT2642989T/pt unknown
- 2011-11-10 CA CA2815390A patent/CA2815390C/en active Active
- 2011-11-10 EP EP11843788.8A patent/EP2642989B1/en active Active
- 2011-11-10 DK DK11843788.8T patent/DK2642989T3/da active
- 2011-11-10 EP EP18207689.3A patent/EP3485883B1/en active Active
- 2011-11-10 HU HUE11843788A patent/HUE042676T2/hu unknown
- 2011-11-10 ES ES18207689T patent/ES2829620T3/es active Active
- 2011-11-10 SI SI201131693T patent/SI2642989T1/sl unknown
- 2011-11-10 RS RS20190411A patent/RS58603B1/sr unknown
- 2011-11-10 WO PCT/AU2011/001455 patent/WO2012068612A1/en active Application Filing
- 2011-11-10 CN CN201180056738.4A patent/CN103228275B/zh active Active
- 2011-11-10 SG SG2013026406A patent/SG189326A1/en unknown
- 2011-11-10 AU AU2011334592A patent/AU2011334592C1/en active Active
- 2011-11-10 JP JP2013540174A patent/JP5942131B2/ja active Active
- 2011-11-10 PL PL11843788T patent/PL2642989T3/pl unknown
- 2011-11-10 DK DK18207689.3T patent/DK3485883T3/da active
- 2011-11-10 KR KR1020137011658A patent/KR101899613B1/ko active IP Right Grant
- 2011-11-10 NZ NZ609144A patent/NZ609144A/en unknown
- 2011-11-10 TR TR2019/04760T patent/TR201904760T4/tr unknown
- 2011-11-10 ES ES11843788T patent/ES2722723T3/es active Active
- 2011-11-10 MX MX2013005561A patent/MX352517B/es active IP Right Grant
- 2011-11-10 US US13/989,677 patent/US9839640B2/en active Active
-
2013
- 2013-04-12 ZA ZA2013/02638A patent/ZA201302638B/en unknown
-
2017
- 2017-11-08 US US15/807,166 patent/US10786510B2/en active Active
- 2017-11-08 US US15/807,282 patent/US10695353B2/en active Active
- 2017-11-08 US US15/807,235 patent/US20180117050A1/en not_active Abandoned
-
2019
- 2019-03-22 HR HRP20190561TT patent/HRP20190561T1/hr unknown
-
2020
- 2020-08-20 US US16/998,708 patent/US11583535B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3444342T3 (da) | Fremgangsmåder og sammensætninger til behandlingen af lysosomale aflejringssygdomme | |
| DK2882441T3 (da) | Behandling af immunrelaterede og inflammatoriske sygdomme | |
| DK3495387T3 (da) | Bispecifikke anti-VEGF-/anti-ANG-2-antistoffer og deres anvendelse ved behandling af okulære vaskulære sygdomme | |
| DK2774616T3 (da) | Anvendelse af roseburia i behandling og forebyggelse af fedmerelaterede sygdomme | |
| DK2688557T3 (da) | Fremgangsmåder og sammensætninger til behandling af forstyrelse af opmærksomhed | |
| EP3071193A4 (en) | Compositions and methods for treatment of ocular inflammation and pain | |
| EP2621499A4 (en) | METHODS OF TREATING ALLERGIC DISEASES | |
| DK2877184T3 (da) | Sammensætninger og behandling for øjensygdomme og -lidelser | |
| DK2747763T3 (da) | (bacterio-)chlorofyllfotosensibilisatorer til behandling af øjensygdomme og -lidelser | |
| EP2890440A4 (en) | DEVICES AND METHOD FOR THE TREATMENT OF VASCULAR DISEASES | |
| DK2726511T3 (da) | Sammensætninger, anvendelser og fremgangsmåder til behandling af stofskiftesygdomme og -lidelser | |
| DK2663864T3 (da) | Fremgangsmåde til at vurdere immundiversitet og anvendelse af denne | |
| EP2819687A4 (en) | COMPOSITIONS AND METHODS FOR TREATING PERIPHERAL VASCULAR DISEASE | |
| DK2723347T3 (da) | Forebyggelse og behandling af inflammationstilstande | |
| FI20135146L (fi) | Farmaseuttiset koostumukset ja hoitomenetelmät | |
| DK2793895T3 (da) | Fremgangsmåder og sammensætninger til reducering af kropsfedt og adipocytter | |
| DK2538986T3 (da) | Intraartikulært supplement til anvendelse til behandling af ledsygdomme og -skader | |
| DK2717914T3 (da) | Depotformuleringer til administration af proteiner til øjet og fremgangsmåder til fremstilling deraf | |
| DK2917231T3 (da) | Lipopeptider til anvendelse ved behandling af leversygdomme og hjerte-kar-sygdomme | |
| DK2800575T3 (da) | Behandling af subarachnoidalblødning og iskæmi | |
| DK2549995T3 (da) | Brug af anatabin til behandling af inflammation og metoder til syntetisering af anatabin | |
| DK2892556T3 (da) | Sammensætninger og fremgangsmåder til behandling af sygdomme | |
| DK3121198T3 (da) | Rekombinant human g-csf-dimer og anvendelse deraf til behandlingen af neurologiske sygdomme | |
| DK2780059T3 (da) | Medicinsk anordning og fremgangsmåde til begrænsning af anvendelsen af den medicinske anordning | |
| IL235874A0 (en) | Treatment of ocular inflammatory diseases by laquinimod |